Home › Funds › TCG Crossover Management, LLC › SYRE
TCG Crossover Management, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
TCG Crossover Management, LLC reported holding 1,900,582 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$168.7M, representing 4.06% of its reported portfolio and ranking #6 among its reported holdings. TCG Crossover Management, LLC has disclosed SYRE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's SYRE position evolved
TCG Crossover Management, LLC first disclosed a stake in SYRE in Q3 2025 at 1,100,582 shares (US$18.4M). The position peaked in Q2 2026 at 1,900,582 shares, worth US$168.7M. Across 4 filings, TCG Crossover Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,900,582 shares valued at US$168.7M. Notable position changes include a 73% increase in Q4 2025 (shares rose 54% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.10M | $18.45M | New |
| Q4 2025 | 1.90M | $62.26M | Add |
| Q1 2026 | 1.90M | $95.87M | Hold |
| Q2 2026 | 1.90M | $168.73M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K sh · $85.99M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
- EMERALD ADVISERS, LLC 567.43K sh · $50.38M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held SYRE?
TCG Crossover Management, LLC has disclosed SYRE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is TCG Crossover Management, LLC's current position in SYRE?
As of Q2 2026, TCG Crossover Management, LLC holds 1.90M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $168.73M, representing 4.06% of its reported portfolio and ranking #6.
Has TCG Crossover Management, LLC been buying or selling SYRE?
In the latest 13F filing (Q2 2026), TCG Crossover Management, LLC held unchanged its position in SYRE. The position peaked in Q2 2026 at 1.90M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.